• Company
• Dinutuximab beta was designated as an orphan drug
• by Eo, Yun-Ho Sep 12, 2023 05:37am

• Policy
• Pfizer’s ALL drug Besponsa renews RSA in KOR
• by Lee, Tak-Sun Sep 12, 2023 05:37am

• Policy
• Vytorin generics suffer blow from reevaluations
• by Lee, Tak-Sun Sep 11, 2023 05:30am

• Company
• Different progress of three new asthma drugs launched
• by Eo, Yun-Ho Sep 11, 2023 05:29am

• Company
• Rebamipide survives reimb evaluations...a relief
• by Chon, Seung-Hyun Sep 11, 2023 05:29am

• Opinion
• [Reporter's view] Obesity-themed stocks
• by Lee, Seok-Jun Sep 11, 2023 05:29am

• Company
• 2nd-gen CML drug approved for reimb following 4th-gen drug
• by Eo, Yun-Ho Sep 11, 2023 05:29am

• Company
• The generic for exclusivity period for Vemlidy ends
• by Kim, Jin-Gu Sep 8, 2023 05:34am

• Policy
• Next year's new drug R&D budget: 58 billion won
• by Lee, Jeong-Hwan Sep 8, 2023 05:34am

• Product
• Phentermine and Saxenda has most reported adverse events
• by Lee, Jeong-Hwan Sep 8, 2023 05:33am